Precision Medicine: MRI-Guided Stereotactic Ablative Radiotherapy (MRI-SABR) for Early-Stage Glottic Laryngeal Cancer

This randomized phase III trial will compare the outcomes of three treatment modalities for early-stage glottic laryngeal cancer (T1-T2N0): transoral CO₂ laser microsurgery (TLM), volumetric modulated arc therapy (VMAT), and MRI-guided stereotactic ablative radiotherapy (MRI-SABR). The primary endpoint is local control (LC). Secondary endpoints include laryngectomy-free survival (LFS), progression-free survival (PFS). overall survival (OS), functional voice, swallowing and breathing outcomes, treatment-related complications, and the evaluation of radiomic and dosiomic biomarkers. Patients will

Trial Details

NCT ID
NCT07391345
Phase
NA
Sponsor
Viktoras Rudzianskas
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Transoral CO₂ laser cordectomy (Type I-VI depending on tumor localization)
  • VMAT radiotherapy
  • MRI-SABR
Locations (sample)
  • Kaunas, Lithuania|54.90156,23.90909

Key Eligibility Criteria

  • Age ≥18 years.
  • Histologically confirmed squamous cell carcinoma of the glottic larynx, including verrucous carcinoma.
  • Stage T1-T2N0 (8th TNM edition).
  • ECOG performance status 0-2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →